Israel's General Sick Fund has excluded Bayer's antidiabetes drugPrandase (acarbose: marketed in Israel by Agis) from its formulary. GSF patients who need the drug must pay NIS150-NIS180 ($45.31-$54.37) per month for it in the private pharmacy market. The other three smaller funds have not restricted its use.
Prandase was registered by the Ministry of Health over a year ago for non-insulin-dependent diabetes mellitus in patients inadequately controlled by diet alone, or on diet and oral hypoglycemic agents, affecting about 90-100,000 patients. Yoram Kantor, scientific editor of a newsletter for diabeticians, says the GSF is excluding the drug "for political and economic reasons. In the market there are no drugs of the same type. If the patient does not use this drug, he has to use older alternatives which do not meet all the clinical requirements and sometimes cause side effects."
The GSF says that as the MoH has not included Prandase in the basket of pharmaceutical benefits defined by the National Health Insurance, it has asked for an extra NIS30 million to provide the drug. So far, the MoH has refused this request.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze